
FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Learn about the history of immunotherapy > >
about 12 years ago
A Brief History of Immunotherapyabout 12 years ago
Better Biomarker Testing Needed in Immuno-Oncologyabout 12 years ago
Autoimmunity and Limitations of Cancer Vaccinesabout 12 years ago
The Management of Side Effects Associated With Immunotherapiesabout 12 years ago
The Next Wave in Immunotherapy: Combinations